Latest news and press releases about Coherus Oncology, Inc. (CHRS): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Coherus Oncology, Inc. is a biopharmaceutical company primarily focused on the research, development, and commercialization of cancer immunotherapies across the United States. The company's commercialized products include several biosimilar therapies.
Price
| Price | $1.22 |
| Market Cap | $188M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 2.98 |
| EV / EBITDA | -1.12 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -181.73% |
| Return on Invested Capital | -135.38% |
| Return on Assets | -68.50% |
| Gross Margin | 63.55% |
| Operating Margin | -307.43% |
| Net Margin | -257.10% |
Related companies: AVTX · CCCC · CDXS · IMDX · IVVD · OABI · PLX
Explore sector: Healthcare · Biotechnology
More sections of CHRS: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks